Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Caribou Biosciences Inc

CRBU
Current price
2.09 USD -0.11 USD (-5.00%)
Last closed 2.2 USD
ISIN US1420381089
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 242 681 248 USD
Yield for 12 month -55.25 %
1Y
3Y
5Y
10Y
15Y
CRBU
21.11.2021 - 28.11.2021

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. Address: 2929 7th Street, Berkeley, CA, United States, 94710

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.75 USD

P/E ratio

Dividend Yield

Current Year

+34 477 000 USD

Last Year

+13 851 000 USD

Current Quarter

+2 024 000 USD

Last Quarter

+3 464 000 USD

Current Year

+30 952 000 USD

Last Year

+10 210 000 USD

Current Quarter

+2 024 000 USD

Last Quarter

+2 608 000 USD

Key Figures CRBU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -161 700 000 USD
Operating Margin TTM -1859.59 %
PE Ratio
Return On Assets TTM -25.75 %
PEG Ratio
Return On Equity TTM -43.6 %
Wall Street Target Price 15.75 USD
Revenue TTM 11 475 000 USD
Book Value 3.11 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -91.4 %
Dividend Yield
Gross Profit TTM -68 379 000 USD
Earnings per share -1.66 USD
Diluted Eps TTM -1.66 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRBU

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRBU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CRBU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.5066
Price Sales TTM 21.1487
Enterprise Value EBITDA -36.9426
Price Book MRQ 0.8598

Financials CRBU

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRBU

For 52 weeks

1.5 USD 8.33 USD
50 Day MA 2.01 USD
Shares Short Prior Month 11 672 513
200 Day MA 3.38 USD
Short Ratio 14.05
Shares Short 11 510 503
Short Percent 13.35 %